Naloxone formulations for sublingual and/or buccal administration
AssigneePharmaceutical Productions Inc.
InventorJohn A. McCarty
Life of this patent
Estimating the term…
Abstract
Liquid, gel, and semi-solid compositions containing naloxone base, or isomers or derivatives thereof, with one or more non-aqueous solvents, and optional viscosity adjusting agents, are provided. Methods of treating an individual exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose including administering a liquid, gel, or semi-solid formulation containing a solution of naloxone base, or an isomer or a derivative thereof, in one or more non-aqueous solvents, are also provided.
Claims13
A liquid, gel or semi-solid pharmaceutical composition comprising:
- from about 1% to about 25% of naloxone base, or an isomer or a derivative thereof, by the total mass of the composition;
- and
- from about 50% to about 99% of one or more non-aqueous solvents selected from the group consisting of oleic acid, liquid polyethylene glycol, propylene glycol, and ethanol, or mixtures thereof, by the total mass of the composition;
- wherein the naloxone base, or isomer or derivative thereof, is completely and homogeneously dissolved in the one or more non-aqueous solvents.
A method for treating an individual exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose comprising the steps of:
- (a) providing a single unit dosage form comprising a solution of naloxone base, or an isomer or a derivative thereof, as a completely, homogeneously dissolved solute in one or more non-aqueous solvents;
- and
- (b) administering the single unit dosage form sublingually or buccally to the individual.
Dependencies are inferred from the claim text.